Contact the Editorial Desk

Editorial correspondence

Best Peptide welcomes correspondence about the research record itself: a citation quoted inaccurately, a clinical trial that has published new results, a regulatory status update, or a peer-reviewed study on CJC-1295, ipamorelin, KPV, retatrutide, or semaglutide that belongs on the references page. Corrections that improve the accuracy or currency of this desk are the most useful messages it receives.

The most actionable submissions specify the page in question, the exact passage being challenged, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed change can be checked against its source before anything is revised.

Editorial mailbox: editors@bestpeptide.org

What this desk cannot do

Best Peptide is a literature digest, not a clinical service or a vendor, so it cannot advise on or recommend human use of any peptide discussed here, suggest a dose or schedule for any individual, evaluate whether a cited finding applies to a specific person's situation, or help locate, source, or purchase any compound from any supplier. It cannot provide guidance on obtaining prescription medicine outside a licensed prescriber relationship, and it cannot advise athletes on anti-doping status for any compound.

Semaglutide is available only by prescription. Retatrutide is investigational and not legally available outside clinical trials. CJC-1295, ipamorelin, and KPV are unapproved research chemicals. Readers seeking clinical guidance should consult a licensed healthcare provider. Responses to editorial correspondence are not guaranteed and may be delayed.